Francesco Bruno

Long-Term Outcome of Molecularly Defined Oligodendrogliomas

Francesco Bruno, Edoardo Pronello, Luca Bertero, Alessia Pellerino et autres

BACKGROUND AND OBJECTIVES: Molecularly defined oligodendrogliomas are rare tumors whose prognosis has improved over time because of more effective treatments. However, several aspects of management are still controversial, and studies with long-term follow-up are needed. The main aim of this study was …

it, by (code pays fourni par la source)

SURG-100. The favorable associations between age and supramaximal resection with outcome in glioblastoma – a report of the RANO resect group

Antonio Dono, Nico Teske, Jacob S. Young, Stephanie T Juenger et autres

Abstract BACKGROUND The oncological role of resection in elderly patients with glioblastoma remains controversial. We compared the prognostic impact of residual tumor volume between elderly and younger patients with (I) newly diagnosed and (II) recurrent glioblastoma to develop individualized surgical strategies and …

us, de, br, ch, it, nl (code pays fourni par la source)

Associations of supramaximal resection with outcome in glioblastoma across age groups: A report of the RANO resect group

Nico Teske, Antonio Dono, Jacob S. Young, Stephanie T Juenger et autres

ABSTRACT: BackgroundThe oncological role of resection in elderly patients with glioblastoma remains controversial. We evaluated the value of resection in patients ≥65 years with (1) newly diagnosed and (2) recurrent glioblastoma by comparing the prognostic relevance of extent of resection to patients …

de, us, ch, it, nl (code pays fourni par la source)

P17.39.A IMPACT OF FRAILTY ON SURGICAL OUTCOMES IN PATIENTS AFFECTED BY GLIOBLASTOMA: A MULTICENTER ANALYSIS WITH MULTIVARIATE AND MACHINE LEARNING APPROACHES.

Maria Caffo, Luana Conte, G Caruso, Tamara Ius et autres

Abstract BACKGROUND Frailty, a multidimensional syndrome characterized by reduced physiological reserves and increased vulnerability to stressors, has emerged as a critical determinant in treatment decision-making and is considered a determining factor in surgical eligibility for patients suffering of glioblastoma, frequently leading to …

it, ar, fr (code pays fourni par la source)

OS08.6.A A PROGNOSTIC CLASSIFICATION SYSTEM FOR EXTENT OF RESECTION IN IDH-MUTANT GRADE 2 GLIOMA: A REPORT BY THE RANO RESECT GROUP

Philipp Karschnia, Jacob Young, Maarten M.J. Wijnenga, Tommaso Sciortino et autres

Abstract BACKGROUND The effects of resection in IDH-mutant grade 2 gliomas remain controversial since terminology for extent of resection was inconsistent across trials. We aimed to (I) establish a standardized classification system for extent of resection and (II) assess the impact of …

de, us, nl, it, se, kr, ch, no (code pays fourni par la source)

Rare gliomas: standard treatment approaches and new target therapies

Francesco Bruno, Alessia Pellerino, Edoardo Pronello, Roberta Rudà

PURPOSE OF REVIEW: Rare gliomas, including circumscribed astrocytic, glioneuronal, and neuronal central nervous system (CNS) tumours, though collectively uncommon, present significant clinical challenges due to their heterogeneity and limited therapeutic evidence. Conventional management has relied predominantly on surgery and radiotherapy. Advances in …

it (code pays fourni par la source)

STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome

Alessia Pellerino, Neibla Priego, Luca Bertero, Alessia Andrea Ricci et autres

BACKGROUND: A high pSTAT3 expression in reactive astrocytes surrounding brain metastases (BrM) promotes tumor growth in preclinical models. The impact of STAT3 expression on outcome of patients with BrM from breast cancer is unknown. METHODS: The expression of pSTAT3 in reactive astrocytes …

it, es, by (code pays fourni par la source)

Early seizure freedom with [ 18 F ]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report

Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello et autres

Abstract Vorasidenib, a dual isocitrate dehydrogenase 1/2 (IDH1/2) inhibitor, showed superior efficacy in prolonging progression‐free survival and time to next intervention in IDH ‐mutant grade 2 gliomas. This case is part of an ongoing institutional study exploring the impact of vorasidenib on …

it, by (code pays fourni par la source)

RANO seizure working group-Tumor-Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice

Edward K. Avila, Anne S. Reiner, Terri S. Armstrong, Ashley Aaroe et autres

BACKGROUND: No standardized method exists for seizure assessment in glioma clinical trials. We describe the development and evaluation of RANO-TREAT (Tumor Related Epilepsy Assessment Tool) for seizure assessment and its association with changes on brain MRI. METHODS: Patients with glioma/glioneuronal tumors and …

us, ua, it, ca, nl, ch (code pays fourni par la source)

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors

Roberta Rudà, Francesco Bruno, Alessia Pellerino, Edoardo Pronello et autres

INTRODUCTION: Adult-type IDH-mutant diffuse gliomas grade 2 are rare tumors mainly affecting young patients, classified by WHO 2021 into IDH-mutant astrocytomas and IDH-mutant 1p/19q codeleted oligodendrogliomas. IDH-mutant grade 2 gliomas are slowly growing tumors; however, they grow continuously, and almost all patients …

it (code pays fourni par la source)

Radiation

Alessia Pellerino, Riccardo Soffietti, Roberta Rudà, Francesco Bruno

it (code pays fourni par la source)

Double fluorescence-guided surgery with 5-ALA and fluorescein sodium in grade 2 and grade 3 adult-type diffuse gliomas: retrospective analysis of 112 cases

Andrea Bianconi, Marta Bonada, Pietro Zeppa, Francesco Bruno et autres

Objective: Fluorescence-guided surgery (FGS) has been increasingly used to support glioma surgery to obtain a maximal extent of resection (EOR). Current evidence in lower-grade gliomas does not support the routine use of FGS obtained with the most common fluorescence agents (e.g. 5-ALA …

it (code pays fourni par la source)